Alberto Bardelli
Impact in
- Cancer Research top 0.02%
- Cancer Genomics and Diagnostics
- Oncology top 0.02%
- Colorectal Cancer Treatments and Studies
- Cancer Cells and Metastasis
Papers in
- Oncology 126
- Colorectal Cancer Treatments and Studies 79
- HER2/EGFR in Cancer Research 15
-
- PI3K/AKT/mTOR signaling in cancer 33
- Protein Kinase Regulation and GTPase Signaling 18
- Co-authors
- Salvatore Siena (78 shared papers)Federica Di Nicolantonio (73 shared papers)Luis A. Díaz (4 shared papers)Andrea Sartore‐Bianchi (60 shared papers)Silvia Marsoni (39 shared papers)Kenneth W. Kinzler (11 shared papers)Bert Vogelstein (11 shared papers)Victor E. Velculescu (11 shared papers)
- Journals
- Annals of Oncology (20 papers)Journal of Clinical Oncology (20 papers)Cancer Research (16 papers)Clinical Cancer Research (11 papers)Cancer Discovery (10 papers)
- Partner nations
- ItalyUnited StatesSpain
In The Last Decade
Alberto Bardelli
260 papers receiving 32.0k citations
Alberto Bardelli's Hit Papers
Peers
Comparison fields: 5 of 161
- Cancer Research 9.0k
- Oncology 13.3k
- Hepatology 3.6k
- Pathology and Forensic Medicine 5.5k
- Molecular Biology 14.5k
Countries citing papers authored by Alberto Bardelli
This map shows the geographic impact of Alberto Bardelli's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Alberto Bardelli with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Alberto Bardelli more than expected).
Fields of papers citing papers by Alberto Bardelli
This network shows the impact of papers produced by Alberto Bardelli. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Alberto Bardelli. The network helps show where Alberto Bardelli may publish in the future.
Co-authors
The 25 scholars most cited alongside Alberto Bardelli, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 266 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | High Frequency of Mutations of the PIK3CA Gene in Human Cancers Hit paper breakdown → | 2004 | 2730 |
| 2 | Liquid Biopsies: Genotyping Circulating Tumor DNA Hit paper breakdown → | 2014 | 1659 |
| 3 | Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR Hit paper breakdown → | 2012 | 1487 |
| 4 | Integrating liquid biopsies into the management of cancer Hit paper breakdown → | 2017 | 1430 |
| 5 | Liquid biopsy: monitoring cancer-genetics in the blood Hit paper breakdown → | 2013 | 1394 |
| 6 | Wild-Type BRAF Is Required for Response to Panitumumab or Cetuximab in Metastatic Colorectal Cancer Hit paper breakdown → | 2008 | 1260 |
| 7 | RAF/RAS oncogenes and mismatch-repair status Hit paper breakdown → | 2002 | 991 |
| 8 | A multifunctional docking site mediates signaling and transformation by the hepatocyte growth factor/scatter factor receptor family Hit paper breakdown → | 1994 | 840 |
| 9 | Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study Hit paper breakdown → | 2005 | 771 |
| 10 | Oncogenic Activation of the RAS/RAF Signaling Pathway Impairs the Response of Metastatic Colorectal Cancers to Anti–Epidermal Growth Factor Receptor Antibody Therapies Hit paper breakdown → | 2007 | 670 |
| 11 | PIK3CA Mutations in Colorectal Cancer Are Associated with Clinical Resistance to EGFR-Targeted Monoclonal Antibodies Hit paper breakdown → | 2009 | 602 |
| 12 | Scatter factor and hepatocyte growth factor are indistinguishable ligands for the MET receptor. Hit paper breakdown → | 1991 | 580 |
| 13 | Association of KRAS p.G13D Mutation With Outcome in Patients With Chemotherapy-Refractory Metastatic Colorectal Cancer Treated With Cetuximab Hit paper breakdown → | 2010 | 575 |
| 14 | A Phosphatase Associated with Metastasis of Colorectal Cancer Hit paper breakdown → | 2001 | 539 |
| 15 | Molecular Mechanisms of Resistance to Cetuximab and Panitumumab in Colorectal Cancer Hit paper breakdown → | 2010 | 538 |
| 16 | 1998 | 454 | |
| 17 | 2005 | 444 | |
| 18 | Early‐onset colorectal cancer in young individuals Hit paper breakdown → | 2018 | 423 |
| 19 | 2009 | 415 | |
| 20 | 2004 | 412 |
About Alberto Bardelli
Alberto Bardelli is a scholar working on Oncology, Molecular Biology, Cancer Research, Pulmonary and Respiratory Medicine and Pathology and Forensic Medicine, having authored 266 papers that have together received 32.6k indexed citations. Recurring topics across this work include Colorectal Cancer Treatments and Studies (79 papers), Cancer Genomics and Diagnostics (78 papers), Genetic factors in colorectal cancer (43 papers), Lung Cancer Treatments and Mutations (42 papers), PI3K/AKT/mTOR signaling in cancer (33 papers), Liver physiology and pathology (31 papers), Protein Kinase Regulation and GTPase Signaling (18 papers) and HER2/EGFR in Cancer Research (15 papers). The work is most often cited by research in Cancer Research (9.0k citations), Oncology (13.3k citations), Hepatology (3.6k citations), Pathology and Forensic Medicine (5.5k citations) and Molecular Biology (14.5k citations). Alberto Bardelli has collaborated with scholars based in Italy, United States and Spain. Frequent co-authors include Salvatore Siena, Federica Di Nicolantonio, Luis A. Díaz, Andrea Sartore‐Bianchi, Silvia Marsoni, Kenneth W. Kinzler, Bert Vogelstein, Victor E. Velculescu, Giulia Siravegna and Paolo M. Comoglio. Their work appears in journals such as Annals of Oncology, Journal of Clinical Oncology, Cancer Research, Clinical Cancer Research and Cancer Discovery.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.